Show simple item record

dc.contributor.authorPopat, S
dc.contributor.authorKim, H
dc.contributor.authorAhn, M
dc.contributor.authorYang, J
dc.contributor.authorHan, J
dc.contributor.authorHochmair, M
dc.contributor.authorLee, K
dc.contributor.authorDelmonte, A
dc.contributor.authorCampelo, M
dc.contributor.authorKim, D
dc.contributor.authorGriesinger, F
dc.contributor.authorFelip, E
dc.contributor.authorCalifano, Raffaele
dc.contributor.authorSpira, A
dc.contributor.authorGettinger, S
dc.contributor.authorTiseo, M
dc.contributor.authorHaney, J
dc.contributor.authorKerstein, D
dc.contributor.authorCamidge, D
dc.date.accessioned2019-04-29T09:49:02Z
dc.date.available2019-04-29T09:49:02Z
dc.date.issued2018en
dc.identifier.citationPopat S, Kim HR, Ahn MJ, Yang JCH, Han JY, Hochmair MJ, et al. LBA58 Intracranial efficacy of brigatinib (BRG) vs crizotinib (CRZ) in the phase III ALTA-1L trial. Ann Oncol. 2018;29(suppl_8):746.en
dc.identifier.doi10.1093/annonc/mdy424.070en
dc.identifier.urihttp://hdl.handle.net/10541/621817
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1093/annonc/mdy424.070en
dc.titleIntracranial efficacy of brigatinib (BRG) vs crizotinib (CRZ) in the phase III ALTA-1L trialen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentMedical Oncology, Royal Marsden Hospital, London, UKen
dc.identifier.journalAnnals of Oncologyen
dc.description.noteen]
refterms.dateFOA2020-04-20T13:17:42Z


Files in this item

Thumbnail
Name:
561669.pdf
Size:
107.8Kb
Format:
PDF
Description:
From UNPAYWALL

This item appears in the following Collection(s)

Show simple item record